You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
9 March 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Monday reported positive topline results from a Phase 2 study evaluating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis.The trial met its primary endpo...
9 March 2026 - Clinical stage gene editing company Precision BioSciences (Nasdaq:DTIL) announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystroph...
9 March 2026 - British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Monday that the US Food and Drug Administration (FDA) has accepted...
9 March 2026 - Zelluna ASA (OSE:ZLNA), a Norway-based company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of cancer, on Monday announced a collaboration with Etcembly Ltd to de...
9 March 2026 - Precision medicine oncology company IDEAYA Biosciences Inc (NASDAQ: IDYA) disclosed on Monday that it has enrolled the first patient in a Phase 1 clinical trial evaluating IDE892, an investigational PRMT5 inhibitor being developed for ...
9 March 2026 - Kelun-Biotech Biopharmaceutical Co, Ltd (6990.HK) announced on Monday that with Harbour BioMed (HKEX: 02142), it has received approval from the National Medical Products Administration in China for an investigational new drug applicati...